Alnylam Pharmaceuticals, Inc. (ALNY) Reports $492M Amvuttra Sales, Raises 2025 Revenue Guidance

We recently collected a list of 12 best health care shares for purchase now. Alnyllam Pharmaceuticals, Inc. It is one of them.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a leading company in the field of biotechnology specialized in intertwining treatments in RNA, to the progress of rare and prevalent diseases, especially surfing through transformation (Attr). The pioneering product, amvuttra (vutrisiran), treats both forms of myocardialism and myocardial illness.

In the second quarter of 2025, AMVUTTRA sales rose to $ 492 million, exceeding $ 350 million, driven by the expanded use of ATTR cardiomyopathy in March 2025. The powerful performance pushed alny to raise its revenue instructions for 2025 for AMVUTTRA and ONPATTRO to 2.18 – 2.28 billion dollars,, With total expected net revenue between $ 2.65 – 2.8 billion dollars. This growth raised the market evaluation of the company over 50 billion dollars, as the shares increased more than 15 % recently.

The second -skinned AMVUTTRA management may enhance adherence to the patient compared to oral competitors such as Tafamidis’s Tafamidis and Bridgebio. At a price of $ 476,000 annually for myocardial illness, it is increasingly used as a treatment from the first line, with the approval of commercial care and medical careers without the use of a prior competitor, which supports sustainable growth in the American market.

Besides commercial success, Alnylam Pharmaceuticals, Inc. Business also provided the third stage data of the Helios-B for 12 months showing sustainable benefits for amvuttra in ATTR heart disease. In addition, Alny joined the genetic discovery alliance in September 2025, as it benefited from genetic data groups on a large scale to accelerate the discovery of the target and innovation in genetic silence treatments.

While we acknowledge the capabilities of Alny as an investment, we believe that some artificial intelligence shares provide greater potential in the upward direction and carry less risks on the negative side. If you are looking for a stock of artificial intelligence with less than very apprecia The best inventory of artificial intelligence in the short term.

Read the following: 30 stocks must double in 3 years and 11 stocks of artificial intelligence to buy now

Detection: Nothing.